Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept
Sign Up to like & getrecommendations! Published in 2017 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-017-0363-z
Abstract: Inhibition of angiogenesis became clinical reality in 2004 with the approval of bevacizumab in metastatic colorectal cancer and we are now approaching the expiration dates of the patents for bevacizumab in the US in July… read more here.
Keywords: concept; angiogenic therapies; cancer entities; cancer ... See more keywords
The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0128-4
Abstract: BackgroundWhile lung adenocarcinoma patients can somewhat benefit from anti-angiogenic therapies, patients with squamous cell lung carcinoma (SQLC) cannot. The reasons for this discrepancy remain largely unknown. Soluble VEGF receptor-1, namely sVEGFR1-i13, is a truncated splice… read more here.
Keywords: cell; angiogenic therapies; anti angiogenic; svegfr1 i13 ... See more keywords
Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.789330
Abstract: Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes… read more here.
Keywords: challenges nanoparticles; treat digestive; digestive tumours; anti angiogenic ... See more keywords